NLS Pharmaceutics Ltd. Merges with Kadimastem Ltd.
Ticker: NCEL · Form: 6-K · Filed: Oct 10, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, acquisition, subsidiary
Related Tickers: KDST
TL;DR
NLS Pharma is merging its Israeli subsidiary with Kadimastem Ltd. to combine operations.
AI Summary
NLS Pharmaceutics Ltd. announced on October 10, 2025, that its wholly owned subsidiary, NLS Pharmaceutics (Israel) Ltd., entered into a Merger Agreement with Kadimastem Ltd. on November 4, 2024. This agreement outlines the terms for Kadimastem to merge with the subsidiary, with Kadimastem being the surviving entity.
Why It Matters
This merger could consolidate resources and expertise, potentially accelerating the development and commercialization of NLS Pharmaceutics' product pipeline.
Risk Assessment
Risk Level: medium — Mergers involve integration challenges and regulatory hurdles that can impact the success of the combined entity.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- NLS Pharmaceutics (Israel) Ltd. (company) — Wholly owned subsidiary of NLS Pharmaceutics Ltd.
- Kadimastem Ltd. (company) — Party to the Merger Agreement
- November 4, 2024 (date) — Date of Merger Agreement
- October 2025 (date) — Reporting period for Form 6-K
FAQ
What is the primary purpose of the merger between NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd.?
The filing indicates that Kadimastem Ltd. will merge with NLS Pharmaceutics (Israel) Ltd., with Kadimastem being the surviving entity, as per the Agreement and Plan of Merger entered into on November 4, 2024.
Which entity will survive the merger?
Kadimastem Ltd. will be the surviving entity of the merger with NLS Pharmaceutics (Israel) Ltd.
When was the Merger Agreement signed?
The Merger Agreement was entered into on November 4, 2024.
What is the relationship between NLS Pharmaceutics Ltd. and NLS Pharmaceutics (Israel) Ltd.?
NLS Pharmaceutics (Israel) Ltd. is a wholly owned subsidiary of NLS Pharmaceutics Ltd.
What is the stock ticker for Kadimastem Ltd.?
Kadimastem Ltd. is an Israeli publicly traded company with the ticker symbol TASE: KDST.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-10-09 20:44:39
Filing Documents
- ea0260720-6k_nlspharma.htm (6-K) — 14KB
- ea026072001ex99-1_nlspharma.htm (EX-99.1) — 247KB
- ea026072001ex99-2_nlspharma.htm (EX-99.2) — 758KB
- ea026072001ex99-3_nlspharma.htm (EX-99.3) — 197KB
- 0001213900-25-097887.txt ( ) — 1217KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 9, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3